Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

BACKGROUND: Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy is frequently used off‐label for clear cell metastatic renal cell carcinoma (mRCC). However, limited data are available to guide such therapy. We performed a meta‐analysis to characterize further the safety and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuanquan, Mori, Sherry V., Li, Mingjia, Hinkley, Megan, Parikh, Anish B., Collier, Katharine A., Miah, Abdul, Yin, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986145/
https://www.ncbi.nlm.nih.gov/pubmed/35138046
http://dx.doi.org/10.1002/cam4.4587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986145/
https://www.ncbi.nlm.nih.gov/pubmed/35138046
http://dx.doi.org/10.1002/cam4.4587

Ejemplares similares